PROCEPT BioRobotics Corporation, a surgical robotics company focused on improving patient care with advanced urology solutions, announced a significant regulatory milestone. Aquablation therapy, a treatment for benign prostatic hyperplasia $(BPH.AU)$, has been assigned a Category I Current Procedural Terminology $(CPT)$ code effective January 1, 2026. This new designation, replacing the previous Category III code, underscores the clinical value and widespread adoption of Aquablation therapy. It is expected to enhance surgeon adoption and broaden patient access, offering a treatment option that provides durable symptom relief with minimal risk of sexual side effects. The 2026 Medicare Proposed Physician Fee Schedule includes this new Category I code, proposing a national average payment of approximately $540, slightly higher than the traditional TURP procedure. The final rule is anticipated in November 2025, with implementation set for January 1, 2026.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.